Hypercalcemia
📧 Sign up to get email alerts when something new happens for Hypercalcemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2015-03-05Clinical Trial Update: Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D [Phase 2, Phase 3]
A Phase 2/3 clinical trial investigating the early effect of Vitamin D in primary hyperparathyroidism has been withdrawn. The study relates …
-
EMA withdrawal · 2011-08-22EMA Application withdrawn: Ibandronic Acid Hexal (ibandronic acid) — Hexal AG
The EMA withdrew the application for Ibandronic Acid Hexal (ibandronic acid) from the market. Therapeutic areas listed include hypercalcemia…
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Destara (ibandronic acid) — Roche Registration Ltd.
Destara (ibandronic acid) has been withdrawn from the European market by Roche Registration Ltd., affecting indications in hypercalcemia and…
-
EMA withdrawal · 2009-05-14EMA Withdrawn: Parareg (cinacalcet) — Dompé Biotec S.p.A.
EMA withdrawn status for Parareg (cinacalcet) by Dompé Biotec S.p.A., with therapeutic areas including hypercalcemia, parathyroid neoplasms,…
-
EMA withdrawal · 2008-11-20EMA Withdrawn: Forcaltonin (recombinant salmon calcitonin) — Unigene UK Ltd.
Forcaltonin (recombinant salmon calcitonin) has been withdrawn from the EMA; previously indicated for hypercalcemia, osteitis deformans, and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.